Could a Sugar-Blocking drug help cystic fibrosis lungs?

NCT ID NCT02325362

Completed Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether miglustat, a drug that blocks certain sugar processing, can improve salt movement in the noses of adults with cystic fibrosis who have the F508del gene mutation. Sixteen participants took miglustat for two weeks and a placebo for two weeks, with a washout period in between. The goal was to see if miglustat could restore function of the faulty CFTR protein.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: miglustat
What this could lead to: If it works, this could point toward a treatment that helps cystic fibrosis patients with the F508del mutation breathe easier.
What could go wrong: This is a very small, early study with only 16 people. It may not show clear benefit, and miglustat can cause side effects like diarrhea or tremors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS

Contacts and locations

Locations

Assistance publique-Hôpitaux de Paris, Hôpital Cochin

Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.